<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530764</url>
  </required_header>
  <id_info>
    <org_study_id>GWCA0701</org_study_id>
    <nct_id>NCT00530764</nct_id>
  </id_info>
  <brief_title>A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.</brief_title>
  <acronym>SPRAY</acronym>
  <official_title>A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GW Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effective dose range and to demonstrate a
      non-effective dose range of Sativex in patients with advanced cancer, who experience
      inadequate pain relief even though they are on optimized chronic opioid therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline</measure>
    <time_frame>5 Weeks: Baseline (first 3 days) - Week 5 (last 3 days)</time_frame>
    <description>A positive 30% pain response is defined as a reduction of at least 30% in the mean NRS average pain score from baseline to week 5 (last 3 days). The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. The average pain NRS was completed at the same time each day, i.e. bedtime in the evening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cumulative Average Pain Response Curves</measure>
    <time_frame>Baseline to end of treatment (Week 5)</time_frame>
    <description>The cumulative response to treatment is the percentage changes from baseline in the mean NRS pain score as defined as the 30% response.
The pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Daily NRS Pain Score (Average Pain).</measure>
    <time_frame>5 Weeks: Baseline (first 3 days) - End of Treatment (last 3 days of week 5)</time_frame>
    <description>The average pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Daily NRS Pain Score (Worst Pain).</measure>
    <time_frame>5 Weeks: Baseline (first 3 days) - End of Treatment (last 3 days of week 5)</time_frame>
    <description>The worst pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your worst pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in worst pain score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Disruption NRS</measure>
    <time_frame>5 Weeks: Baseline - End of Treatment (Last 3 days of Week 5)</time_frame>
    <description>The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?&quot; where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Pain Inventory - Short Form (BPI-SF)</measure>
    <time_frame>Baseline (Visit 2) and End of Treatment (End of Week 5 or premature termination)</time_frame>
    <description>The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). the minimum value is zero and maximum is 10. A higher score represents a poor outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)</measure>
    <time_frame>Baseline (Visit 2) and End of Treatment (Week 5 or premature termination)</time_frame>
    <description>The PAC-QoL questionnaire consists of 28 questions divided into the following areas: 4 questions on physical discomfort, 8 questions on psychosocial discomfort, 11 questions on worries/concerns and 5 questions on satisfaction. The PAC-QoL was completed at baseline and then at the end of treatment. An overall score (range 0-4) was calculated at each visit and the difference determined. A positive difference in score represents an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Change - PGIC</measure>
    <time_frame>End of Week 5</time_frame>
    <description>A 7-point Likert-type scale was used, with the question: 'Please assess the status of your pain due to cancer since entry into the study using the scale below' with the markers &quot;very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse&quot;. At Visit 2 (Baseline) patients wrote a brief description of their pain caused by cancer which was used at Week 5 to aid their memory regarding their symptoms at study start. For each of above markers the number of participants were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline and End of Treatment (Week 5 or premature termination)</time_frame>
    <description>The MADRS comprises of 10 questions that are completed by the patient to determine their depression level. The MADRS was completed at Visit 2 (Baseline) prior to receiving the study drug and at Visit 4 (Week 5 or premature termination). Each item is scored on a 0-6 scale , where 0=no sadness to 6=extreme and continuous gloom and despondency, and the MADRS score is the sum of the 10 item scores (range 0-60). The higher the score the more severe the depression.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Palliative Care</condition>
  <condition>Pain</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Sativex Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sativex Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sativex High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Range of 1-16 sprays per day of placebo spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex Low Dose</intervention_name>
    <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
    <arm_group_label>Sativex Low Dose</arm_group_label>
    <other_name>GW-1000-02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex Medium Dose</intervention_name>
    <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
    <arm_group_label>Sativex Medium Dose</arm_group_label>
    <other_name>GW-1000-02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex High Dose</intervention_name>
    <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
    <arm_group_label>Sativex High Dose</arm_group_label>
    <other_name>GW-1000-02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has advanced active cancer for which there is no known curative therapy.

          -  The patient is able (in the investigators opinion) and willing to comply with all
             study requirements.

          -  The patient has a clinical diagnosis of cancer related pain, which is not wholly
             alleviated with their current opioid treatment.

          -  The patient is receiving a sustained release (SR) fixed dose of opioid therapy
             (excluding Methadone). N.B. The opiate therapy must be Step III according to the World
             Health Organization (WHO) analgesic ladder.

          -  The patient is willing to continue to take their regular daily baseline opioid regimen
             (SR) at the same dose, throughout the duration of study.

        Exclusion Criteria:

          -  The patient should be excluded from entering study if they have received or are due to
             receive during the study period; chemotherapy, hormone therapy or radiotherapy, which,
             in the opinion of the investigator will affect their pain.

          -  Any history or immediate family history of schizophrenia, other psychotic illness,
             severe personality disorder or other significant psychiatric disorder other than
             depression associated with their underlying condition.

          -  Any known or suspected history of a diagnosed dependence disorder, current heavy
             alcohol consumption, current use of an illicit drug or current non prescribed use of
             any prescription drug.

          -  The patient has poorly controlled epilepsy or recurrent seizures (i.e. at least one
             year since last seizure).

          -  The patient has experienced myocardial infarction or clinically relevant cardiac
             dysfunction within the last 12 months or has a cardiac disorder that, in the opinion
             of the investigator would put the patient at risk of a clinically relevant arrhythmia
             or myocardial infarction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Care Center of Tuscaloosa</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Oasis Cancer Center</name>
      <address>
        <city>Casa Grande</city>
        <state>Arizona</state>
        <zip>85222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Coast Hematology/Oncology Medical Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Ronald Yanagihara</name>
      <address>
        <city>Gilroy</city>
        <state>California</state>
        <zip>95020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Institute of Medical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Services</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Hope for Cancer and Blood Disorders</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Associates</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research - Washington County Hospital</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A &amp; A Pain Institute of St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Donald H. Berdeaux MD</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Four Seasons Hospice &amp; Pallative Care</name>
      <address>
        <city>Flat Rock</city>
        <state>North Carolina</state>
        <zip>28731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lone Star Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi (Hôpital civil de Charleroi)</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Algologisch Centrum Anesthesiologie</name>
      <address>
        <city>Pellenberg</city>
        <zip>3212</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Health Research Center</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Radio-oncológico Santiago (INRAD)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Ciudad del Mar</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulance pro lécbu bolesti, ARO</name>
      <address>
        <city>Benešov</city>
        <zip>25601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulance pro lécbu bolesti</name>
      <address>
        <city>Ceské Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Ceské Budejovice</name>
      <address>
        <city>Ceské Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Králové - Klinika onkologie a radioterapie</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN a LF UP Olomouc - Ambulance pro lécbu bolesti</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AR klinika FN Plzen -Ambulance pro lécbu bolesti</name>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Na Bulovce</name>
      <address>
        <city>Praha 8 - Liben</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARO, Krajská zdravotni, K.Z. a.s, Nemocnice</name>
      <address>
        <city>Teplice</city>
        <zip>41501</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Docrates Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00150</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praticien hospitalier</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen Universität</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schmerz- und Palliativzentrum Göppingen</name>
      <address>
        <city>Göppingen</city>
        <zip>73033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Marien-Hospital Lunen</name>
      <address>
        <city>Lunen</city>
        <zip>44534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schmeiz - u Pallielivzendium Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital</name>
      <address>
        <city>Andhra Pradesh</city>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Institute of Oncology</name>
      <address>
        <city>Bangalore,</city>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBCC- Apollo Hospital</name>
      <address>
        <city>Gandhinagar</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indo-American Cancer Institute and Research Center</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwaan Mahaveer Cancer Hospital and Research Centre</name>
      <address>
        <city>Jaipur</city>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHL - Apollo Hospitals</name>
      <address>
        <city>Madhya Pradesh</city>
        <zip>452 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Cancer Hospital</name>
      <address>
        <city>Madhya Pradesh</city>
        <zip>462 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital &amp; Research Centre</name>
      <address>
        <city>Madurai</city>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Centre Pvt. Ltd.</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Center</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seroc Cancer Center</name>
      <address>
        <city>Rajasthan</city>
        <zip>302 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regina Elana Cancer Institute</name>
      <address>
        <city>Rom</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dir. S.C.D.U. Psicologia Clinica ed Oncologica</name>
      <address>
        <city>Turin</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aranda de la Parra</name>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Htal Ángeles de Pedregal</name>
      <address>
        <city>Mexico DF</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beskidzkie Centrum Onkologii im. Jana Pawla</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Leczenia Bolu</name>
      <address>
        <city>Edyty Jakubow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Hospicjum Milosierdzia Bozego</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>31-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wielkopolskie Centrum Onkologii</name>
      <address>
        <city>Poznan</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. M. Sklodowskiej - Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta &quot;Constantin Opris&quot;</name>
      <address>
        <city>Baia Mare, Maramures</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta Braila</name>
      <address>
        <city>Braila, Jud. Braila</city>
        <zip>810325</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospice &quot;Casa Sperantei&quot;</name>
      <address>
        <city>Brasov</city>
        <zip>500074</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Elias</name>
      <address>
        <city>Bucuresti</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. IanuliMed S.R.L. Oncologie Medicala</name>
      <address>
        <city>Bucuresti</city>
        <zip>020962</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policnica Orizont-Oncologie Medicala</name>
      <address>
        <city>Craiova</city>
        <zip>200535</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Hospital Dr. Alexandru Simionescu</name>
      <address>
        <city>Hunedoara</city>
        <zip>331057</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Medicala</name>
      <address>
        <city>Iasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Municipal Onesti</name>
      <address>
        <city>Onesti, Jud. Bacau</city>
        <zip>601048</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Municipal Ploiesti</name>
      <address>
        <city>Ploiesti</city>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Sibiu Oncologie</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta &quot;Sf. Ioan cel Nou&quot;</name>
      <address>
        <city>Suceava</city>
        <zip>720237</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Pirjol &amp; Szpak Inc.</name>
      <address>
        <city>Amanzimtoti</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi Clinic</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Clinic</name>
      <address>
        <city>Cape Town</city>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria Urology Research Unit</name>
      <address>
        <city>Hatfield, Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trialtech Research - Embassy Drive Medical Centre</name>
      <address>
        <city>Hatfield, Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology/Haematology Dept Research Unit</name>
      <address>
        <city>Kimberley</city>
        <zip>8301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastleigh Breast Cancer Center</name>
      <address>
        <city>Lynnwood</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Mar</name>
      <address>
        <city>Almeria</city>
        <zip>04003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU Puerta del Mar, Oncologia</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Feixa, Llarga, sn</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>180114</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Rioja</name>
      <address>
        <city>Logrono</city>
        <zip>26001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Los Montalvos</name>
      <address>
        <city>Salamanca</city>
        <zip>37192</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke &amp; North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St Edmunds</city>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury, Lancashire</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Research Centre (CRUK)</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget Hospital</name>
      <address>
        <city>Gorleston on Sea, Norfolk</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Observatory on End of Life Care</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4YT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marie Curie Hospice Holme Tower</name>
      <address>
        <city>Penarth</city>
        <zip>CF64 3YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Area Health Trust</name>
      <address>
        <city>Weston super Mare</city>
        <zip>BS23 4TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012 May;13(5):438-49. doi: 10.1016/j.jpain.2012.01.003. Epub 2012 Apr 5.</citation>
    <PMID>22483680</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <results_first_submitted>March 2, 2011</results_first_submitted>
  <results_first_submitted_qc>June 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2011</results_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Cancer</keyword>
  <keyword>Palliative</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sativex High Dose Group</title>
          <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
        </group>
        <group group_id="P2">
          <title>Sativex Medium Dose Group</title>
          <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
        </group>
        <group group_id="P3">
          <title>Sativex Low Dose Group</title>
          <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Range of 1-16 sprays per day of placebo spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sativex High Dose Group</title>
          <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
        </group>
        <group group_id="B2">
          <title>Sativex Medium Dose Group</title>
          <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
        </group>
        <group group_id="B3">
          <title>Sativex Low Dose Group</title>
          <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Range of 1-16 sprays per day of placebo spray</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="91"/>
            <count group_id="B4" value="91"/>
            <count group_id="B5" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="11.2"/>
                    <measurement group_id="B2" value="59" spread="31.1"/>
                    <measurement group_id="B3" value="59" spread="12.3"/>
                    <measurement group_id="B4" value="56" spread="12.2"/>
                    <measurement group_id="B5" value="58" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline</title>
        <description>A positive 30% pain response is defined as a reduction of at least 30% in the mean NRS average pain score from baseline to week 5 (last 3 days). The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. The average pain NRS was completed at the same time each day, i.e. bedtime in the evening.</description>
        <time_frame>5 Weeks: Baseline (first 3 days) - Week 5 (last 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline</title>
          <description>A positive 30% pain response is defined as a reduction of at least 30% in the mean NRS average pain score from baseline to week 5 (last 3 days). The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. The average pain NRS was completed at the same time each day, i.e. bedtime in the evening.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="0.46" upper_limit="1.76"/>
                    <measurement group_id="O2" value="26" lower_limit="0.62" upper_limit="2.28"/>
                    <measurement group_id="O3" value="30" lower_limit="0.72" upper_limit="2.60"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The proportions of responders were compared between the treatment groups using logistic regression with region and treatment groups as factors. The null hypothesis was that there was no difference between each of the Sativex treatment groups and placebo. The estimated response rates, odds ratios, 95% CIs for the odds ratios and p-values were presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex Low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex Low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cumulative Average Pain Response Curves</title>
        <description>The cumulative response to treatment is the percentage changes from baseline in the mean NRS pain score as defined as the 30% response.
The pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer.</description>
        <time_frame>Baseline to end of treatment (Week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cumulative Average Pain Response Curves</title>
          <description>The cumulative response to treatment is the percentage changes from baseline in the mean NRS pain score as defined as the 30% response.
The pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" lower_limit="-30" upper_limit="6"/>
                    <measurement group_id="O2" value="-20" lower_limit="-40" upper_limit="-6"/>
                    <measurement group_id="O3" value="-20" lower_limit="-48" upper_limit="-8"/>
                    <measurement group_id="O4" value="-10" lower_limit="-33" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Each of the active treatment groups were compared with placebo using pairwise Wilcoxon rank-sum tests. The Hodges-Lehmann estimates and 95% CI for the median differences were also presented.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>Wilcoxon rank sum tests</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-12.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.35</ci_lower_limit>
            <ci_upper_limit>-3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Wilcoxin rank sum test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.04</ci_lower_limit>
            <ci_upper_limit>7.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Wilcoxin rank sum test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-8.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.14</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Daily NRS Pain Score (Average Pain).</title>
        <description>The average pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.</description>
        <time_frame>5 Weeks: Baseline (first 3 days) - End of Treatment (last 3 days of week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Daily NRS Pain Score (Average Pain).</title>
          <description>The average pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.</description>
          <units>Points on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.9" lower_limit="-6.3" upper_limit="2.3"/>
                    <measurement group_id="O2" value="-1.2" spread="1.7" lower_limit="-7.3" upper_limit="5.7"/>
                    <measurement group_id="O3" value="-1.6" spread="2.1" lower_limit="-8.0" upper_limit="3.3"/>
                    <measurement group_id="O4" value="-0.8" spread="1.8" lower_limit="-6.0" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change in mean pain NRS score (average pain) was analyzed using analysis of covariance (ANCOVA) with the baseline value as a covariate and region and treatment group as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment effect</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment effect</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment effect</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Daily NRS Pain Score (Worst Pain).</title>
        <description>The worst pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your worst pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in worst pain score from baseline.</description>
        <time_frame>5 Weeks: Baseline (first 3 days) - End of Treatment (last 3 days of week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Daily NRS Pain Score (Worst Pain).</title>
          <description>The worst pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate the number that best describes your worst pain in the last 24 hours&quot; where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in worst pain score from baseline.</description>
          <units>Points on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.9"/>
                    <measurement group_id="O2" value="-1.2" spread="1.8"/>
                    <measurement group_id="O3" value="-1.6" spread="2.2"/>
                    <measurement group_id="O4" value="-0.9" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change in mean pain NRS score (worst pain) was analyzed using ANCOVA with the baseline value as a covariate and region and treatment group as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment effect</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated treatment effect</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated Treatment Effect</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Disruption NRS</title>
        <description>The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?&quot; where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.</description>
        <time_frame>5 Weeks: Baseline - End of Treatment (Last 3 days of Week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Disruption NRS</title>
          <description>The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked &quot;on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?&quot; where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.</description>
          <units>Points on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.1" lower_limit="-1.45" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="-0.9" spread="2.1" lower_limit="-1.45" upper_limit="-0.31"/>
                    <measurement group_id="O3" value="-1.5" spread="2.1" lower_limit="-1.45" upper_limit="-0.31"/>
                    <measurement group_id="O4" value="-0.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change in mean sleep disturbance NRS score was analyzed using ANCOVA with the baseline value as a covariate and region and treatment group as factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated Treatment Effect</param_type>
            <param_value>-0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.45</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated Treatment Effect</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As for Sativex low dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated Treatment Effect</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brief Pain Inventory – Short Form (BPI-SF)</title>
        <description>The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). the minimum value is zero and maximum is 10. A higher score represents a poor outcome.</description>
        <time_frame>Baseline (Visit 2) and End of Treatment (End of Week 5 or premature termination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brief Pain Inventory – Short Form (BPI-SF)</title>
          <description>The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). the minimum value is zero and maximum is 10. A higher score represents a poor outcome.</description>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.9" lower_limit=".09" upper_limit=".34"/>
                    <measurement group_id="O2" value="-1.5" spread="1.6" lower_limit=".09" upper_limit=".34"/>
                    <measurement group_id="O3" value="-1.3" spread="2.3" lower_limit=".09" upper_limit=".34"/>
                    <measurement group_id="O4" value="-1.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)</title>
        <description>The PAC-QoL questionnaire consists of 28 questions divided into the following areas: 4 questions on physical discomfort, 8 questions on psychosocial discomfort, 11 questions on worries/concerns and 5 questions on satisfaction. The PAC-QoL was completed at baseline and then at the end of treatment. An overall score (range 0-4) was calculated at each visit and the difference determined. A positive difference in score represents an improvement.</description>
        <time_frame>Baseline (Visit 2) and End of Treatment (Week 5 or premature termination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)</title>
          <description>The PAC-QoL questionnaire consists of 28 questions divided into the following areas: 4 questions on physical discomfort, 8 questions on psychosocial discomfort, 11 questions on worries/concerns and 5 questions on satisfaction. The PAC-QoL was completed at baseline and then at the end of treatment. An overall score (range 0-4) was calculated at each visit and the difference determined. A positive difference in score represents an improvement.</description>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.7" lower_limit="-0.04" upper_limit="0.26"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5" lower_limit="-0.04" upper_limit="0.26"/>
                    <measurement group_id="O3" value="0.0" spread="0.6" lower_limit="-0.04" upper_limit="0.26"/>
                    <measurement group_id="O4" value="-0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient Global Impression of Change - PGIC</title>
        <description>A 7-point Likert-type scale was used, with the question: ‘Please assess the status of your pain due to cancer since entry into the study using the scale below’ with the markers “very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse”. At Visit 2 (Baseline) patients wrote a brief description of their pain caused by cancer which was used at Week 5 to aid their memory regarding their symptoms at study start. For each of above markers the number of participants were reported.</description>
        <time_frame>End of Week 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Global Impression of Change - PGIC</title>
          <description>A 7-point Likert-type scale was used, with the question: ‘Please assess the status of your pain due to cancer since entry into the study using the scale below’ with the markers “very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse”. At Visit 2 (Baseline) patients wrote a brief description of their pain caused by cancer which was used at Week 5 to aid their memory regarding their symptoms at study start. For each of above markers the number of participants were reported.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="0.46" upper_limit="1.49"/>
                    <measurement group_id="O2" value="6" lower_limit="0.49" upper_limit="1.58"/>
                    <measurement group_id="O3" value="10" lower_limit="0.77" upper_limit="2.53"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS comprises of 10 questions that are completed by the patient to determine their depression level. The MADRS was completed at Visit 2 (Baseline) prior to receiving the study drug and at Visit 4 (Week 5 or premature termination). Each item is scored on a 0-6 scale , where 0=no sadness to 6=extreme and continuous gloom and despondency, and the MADRS score is the sum of the 10 item scores (range 0-60). The higher the score the more severe the depression.</description>
        <time_frame>Baseline and End of Treatment (Week 5 or premature termination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sativex High Dose Group</title>
            <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
          </group>
          <group group_id="O2">
            <title>Sativex Medium Dose Group</title>
            <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
          </group>
          <group group_id="O3">
            <title>Sativex Low Dose Group</title>
            <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Range of 1-16 sprays per day of placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS comprises of 10 questions that are completed by the patient to determine their depression level. The MADRS was completed at Visit 2 (Baseline) prior to receiving the study drug and at Visit 4 (Week 5 or premature termination). Each item is scored on a 0-6 scale , where 0=no sadness to 6=extreme and continuous gloom and despondency, and the MADRS score is the sum of the 10 item scores (range 0-60). The higher the score the more severe the depression.</description>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="8.6" lower_limit="0.38" upper_limit="3.74"/>
                    <measurement group_id="O2" value="-1.0" spread="8.5" lower_limit="0.38" upper_limit="3.74"/>
                    <measurement group_id="O3" value="-1.1" spread="7.0" lower_limit="0.38" upper_limit="3.74"/>
                    <measurement group_id="O4" value="-2.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events (AEs) occurring from the time of consent to post study follow up (Visit 5) i.e.9 weeks were collected. All deaths and serious adverse events (SAEs) occurring within 28 days of the final dose of study medication were also collected.</time_frame>
      <desc>All AEs occurring during the study were reported on the running logs at the back of the study case report form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sativex High Dose Group</title>
          <description>Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.</description>
        </group>
        <group group_id="E2">
          <title>Sativex Medium Dose Group</title>
          <description>Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.</description>
        </group>
        <group group_id="E3">
          <title>Sativex Low Dose Group</title>
          <description>Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Range of 1-16 sprays per day of placebo spray</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <description>Any new unfavorable/unintended symptoms, worsening of condition that may/not be considered related to study medication.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (Incl. Cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobillary Disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcuraneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication Policy:
GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications for example, manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Hersch, Senior Clinical Project Manager</name_or_title>
      <organization>GW Pharma Ltd.</organization>
      <phone>+44 1353 616600</phone>
      <email>mhersch@gwpham.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

